| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Immunotoxin therapy of cancer.
|
Nat Rev Cancer
|
2006
|
3.93
|
|
2
|
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
|
Clin Cancer Res
|
2007
|
3.30
|
|
3
|
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.
|
Sci Transl Med
|
2013
|
2.39
|
|
4
|
Immunotoxin treatment of cancer.
|
Annu Rev Med
|
2007
|
2.36
|
|
5
|
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
|
Clin Cancer Res
|
2002
|
2.30
|
|
6
|
Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.
|
Blood
|
2011
|
2.28
|
|
7
|
Localization of mesothelin in epithelial ovarian cancer.
|
Appl Immunohistochem Mol Morphol
|
2005
|
1.84
|
|
8
|
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.
|
Blood
|
2008
|
1.74
|
|
9
|
Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
|
Clin Cancer Res
|
2010
|
1.64
|
|
10
|
VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.
|
Blood
|
2009
|
1.59
|
|
11
|
Evidence of canonical somatic hypermutation in hairy cell leukemia.
|
Blood
|
2011
|
1.55
|
|
12
|
In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin.
|
J Biol Chem
|
2004
|
1.54
|
|
13
|
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.
|
Cancer Res
|
2011
|
1.54
|
|
14
|
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
|
J Immunol
|
2007
|
1.52
|
|
15
|
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.
|
Proc Natl Acad Sci U S A
|
2012
|
1.42
|
|
16
|
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
|
J Immunol
|
2006
|
1.42
|
|
17
|
PRAME expression in hairy cell leukemia.
|
Leuk Res
|
2008
|
1.41
|
|
18
|
New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA.
|
Clin Cancer Res
|
2005
|
1.39
|
|
19
|
Immunotoxins for leukemia.
|
Blood
|
2014
|
1.33
|
|
20
|
HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.
|
Clin Cancer Res
|
2005
|
1.32
|
|
21
|
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.
|
Proc Natl Acad Sci U S A
|
2011
|
1.29
|
|
22
|
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
|
Cancer
|
2014
|
1.24
|
|
23
|
Variables affecting the quantitation of CD22 in neoplastic B cells.
|
Cytometry B Clin Cytom
|
2010
|
1.21
|
|
24
|
Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins.
|
Blood
|
2003
|
1.17
|
|
25
|
Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
|
Clin Cancer Res
|
2002
|
1.15
|
|
26
|
CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.
|
Clin Cancer Res
|
2009
|
1.10
|
|
27
|
Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene.
|
Am J Clin Pathol
|
2003
|
1.09
|
|
28
|
Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.
|
J Immunother
|
2006
|
1.03
|
|
29
|
Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders.
|
Am J Clin Pathol
|
2011
|
0.98
|
|
30
|
Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies.
|
Clin Cancer Res
|
2005
|
0.97
|
|
31
|
Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.
|
Leuk Res
|
2013
|
0.97
|
|
32
|
Thrombotic microangiopathy with targeted cancer agents.
|
Clin Cancer Res
|
2011
|
0.96
|
|
33
|
Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression.
|
Br J Haematol
|
2009
|
0.92
|
|
34
|
Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.
|
Protein Expr Purif
|
2004
|
0.90
|
|
35
|
Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction.
|
Clin Cancer Res
|
2006
|
0.89
|
|
36
|
Soluble CD22 as a tumor marker for hairy cell leukemia.
|
Blood
|
2008
|
0.88
|
|
37
|
Molecular variant of hairy cell leukemia with poor prognosis.
|
Leuk Lymphoma
|
2011
|
0.88
|
|
38
|
Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments.
|
Clin Cancer Res
|
2002
|
0.87
|
|
39
|
Somatic hypermutation and VH gene usage in hairy cell leukaemia.
|
Br J Haematol
|
2006
|
0.87
|
|
40
|
The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.
|
Br J Haematol
|
2014
|
0.86
|
|
41
|
Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.
|
Bioconjug Chem
|
2007
|
0.86
|
|
42
|
Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.
|
Clin Cancer Res
|
2011
|
0.85
|
|
43
|
Immunotoxin therapy of hematologic malignancies.
|
Semin Oncol
|
2003
|
0.84
|
|
44
|
Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy.
|
Cancer Res
|
2005
|
0.83
|
|
45
|
Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy.
|
Cancer Immunol Immunother
|
2005
|
0.82
|
|
46
|
Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma.
|
Blood
|
2012
|
0.81
|
|
47
|
Variables in the quantification of CD4 in normals and hairy cell leukemia patients.
|
Cytometry B Clin Cytom
|
2011
|
0.81
|
|
48
|
Immunotoxins in cancer therapy.
|
Curr Opin Investig Drugs
|
2002
|
0.81
|
|
49
|
Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.
|
Clin Cancer Res
|
2013
|
0.81
|
|
50
|
The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan.
|
MAbs
|
2011
|
0.80
|
|
51
|
Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.
|
Leuk Lymphoma
|
2011
|
0.80
|
|
52
|
Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.
|
Br J Haematol
|
2014
|
0.79
|
|
53
|
CLL immunotoxins.
|
Leuk Res
|
2005
|
0.79
|
|
54
|
Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides.
|
Blood
|
2002
|
0.79
|
|
55
|
Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
|
Ann Thorac Surg
|
2004
|
0.79
|
|
56
|
Characterization of CD22 expression in acute lymphoblastic leukemia.
|
Pediatr Blood Cancer
|
2015
|
0.79
|
|
57
|
The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.
|
Haematologica
|
2011
|
0.79
|
|
58
|
Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia.
|
Cytometry B Clin Cytom
|
2008
|
0.78
|
|
59
|
Multidrug-resistant tumor cells remain sensitive to a recombinant interleukin-4-Pseudomonas exotoxin, except when overexpressing the multidrug resistance protein MRP1.
|
Clin Cancer Res
|
2003
|
0.78
|
|
60
|
Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera.
|
Clin Chem Lab Med
|
2006
|
0.78
|
|
61
|
Response of hairy cell leukemia to bendamustine.
|
Leuk Lymphoma
|
2011
|
0.78
|
|
62
|
Immunoglobulin light chain repertoire in hairy cell leukemia.
|
Leuk Res
|
2007
|
0.78
|
|
63
|
Renal excretion of recombinant immunotoxins containing pseudomonas exotoxin.
|
Bioconjug Chem
|
2011
|
0.78
|
|
64
|
Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia.
|
Am J Clin Pathol
|
2013
|
0.77
|
|
65
|
Taming ricin toxin.
|
Nat Biotechnol
|
2003
|
0.76
|
|
66
|
Treatment of hairy cell leukemia in its second half-century: an International Conference on Hairy Cell Leukemia at the National Institutes of Health, April 26-27, 2010, Bethesda, MD.
|
Leuk Lymphoma
|
2011
|
0.76
|
|
67
|
Augmentation of the activity of an immunotoxin, anti-Tac(Fv)-PE40KDEL, in T cell lines infected with human T cell leukemia virus type-I.
|
Leuk Lymphoma
|
2002
|
0.76
|
|
68
|
Synergistic targeting of leukemia with leukotoxin and chemotherapy.
|
Leuk Res
|
2011
|
0.75
|